Novel and Investigational Treatments for Onychomycosis

Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe emotional stress. Treatment failure and relapse of the infection are the most frequent problems, though new issues have become the new challenges in the therapeutic approach to onychomycosis. Resistance to antifungals, an increasing number of comorbidities, and polydrug use among the ageing population are imperatives that impose a shift to safer drugs. Topical antifungals are considered less toxic and minimally interact with other drugs. The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment disease-free time and a lack of systemic impact on the patients’ health. Efinaconazole, Tavaborole, and Luliconazole have been added to physicians’ weaponry during the last decade, though launched on the market of a limited number of countries. The pipeline is either developing new products (e.g., ME-1111 and NP213) with an appealing combination of pharmacokinetic, efficacy, and safety properties or reformulating old, well-known drugs (Terbinafine and Amphotericin B) by using new excipients as penetration enhancers.

[1]  M. Shams-Ghahfarokhi,et al.  Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani and Fusarium incarnatum‐equiseti species complexes from onychomycosis in north of Iran , 2022, Mycoses.

[2]  A. Concheiro,et al.  Poly(pseudo)rotaxanes formed by mixed micelles and α-cyclodextrin enhance terbinafine nail permeation to deeper layers , 2022, International journal of pharmaceutics: X.

[3]  R. Fuhr,et al.  Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis , 2022, Mycoses.

[4]  S. Hashemi,et al.  The epidemiology and etiology of onychomycosis in 2 laboratory centers affiliated to Tehran university of medical sciences during 2019–2020 , 2022, Iranian journal of microbiology.

[5]  B. Piraccini,et al.  Onychomycosis: Recommendations for Diagnosis, Assessment of Treatment Efficacy, and Specialist Referral. The CONSONANCE Consensus Project , 2022, Dermatology and Therapy.

[6]  Aditya K. Gupta,et al.  Efinaconazole in Onychomycosis , 2021, American Journal of Clinical Dermatology.

[7]  S. Bunyaratavej,et al.  Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: A pilot study , 2021, Indian Journal of Dermatology, Venereology and Leprology.

[8]  Aditya K. Gupta,et al.  27602 Long-term efficacy and safety of once-daily topical efinaconazole 10% topical solution (Jublia) for dermatophyte toenail onychomycosis: An interim analysis , 2021 .

[9]  A. Firooz,et al.  The in vitro effect of nanoliposomal amphotericin B against two clinically important dermatophytes , 2021, International journal of dermatology.

[10]  E. Egito,et al.  Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B–Loaded Nail Lacquer , 2021, Pharmaceutics.

[11]  M. Venkataraman,et al.  Nondermatophyte mould onychomycosis , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  E. Ghelardi,et al.  In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum , 2021, Antimicrobial Agents and Chemotherapy.

[13]  Aditya K. Gupta,et al.  Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. , 2021, Skin therapy letter.

[14]  Aditya K. Gupta,et al.  Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild-to-moderate distal subungual onychomycosis: A randomized, multi-center, double-blind, vehicle-controlled phase 3 study. , 2020, Journal of the American Academy of Dermatology.

[15]  D. Mercer,et al.  NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile , 2020, Medical mycology.

[16]  D. Monti,et al.  Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum , 2019, Antimicrobial Agents and Chemotherapy.

[17]  D. Mercer,et al.  Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate , 2019, Antimicrobial Agents and Chemotherapy.

[18]  Y. Kuwano,et al.  Retrospective Survey of Treatment Outcomes of Efinaconazole 10% Solution and Luliconazole 5% Solution for Onychomycosis in Our Facility. , 2019, Medical mycology journal.

[19]  R. Mays,et al.  Global perspectives for the management of onychomycosis , 2018, International journal of dermatology.

[20]  H. Badali,et al.  Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis , 2018, Antimicrobial Agents and Chemotherapy.

[21]  S. Lipner,et al.  Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies , 2018, The Journal of dermatological treatment.

[22]  H. Maibach,et al.  In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis , 2017, Antimicrobial Agents and Chemotherapy.

[23]  H. Kishida,et al.  Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double‐blind, randomized phase III study , 2017, The Journal of dermatology.

[24]  H. Maibach,et al.  Antifungal ME1111 in vitro human onychopharmacokinetics , 2017, Drug development and industrial pharmacy.

[25]  B. Piraccini,et al.  Onychomycosis in patients with nail psoriasis: a point to point discussion , 2017, Mycoses.

[26]  Aditya K. Gupta,et al.  Tavaborole – a treatment for onychomycosis of the toenails , 2016, Expert review of clinical pharmacology.

[27]  N. Kubota,et al.  [Distribution of Luliconazole in Nail Plate by In Vitro Permeation and Efficacy by Zone of Inhibition Test after Treatment of Luliconazole Nail Solution]. , 2016, Medical mycology journal.

[28]  S. Abe,et al.  Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis , 2015, Antimicrobial Agents and Chemotherapy.

[29]  B. Elewski,et al.  Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. , 2015, Journal of the American Academy of Dermatology.

[30]  T. Rosen,et al.  Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. , 2015, Journal of drugs in dermatology : JDD.

[31]  B. Sigurgeirsson,et al.  The prevalence of onychomycosis in the global population – A literature study , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  J. Lear,et al.  British Association of Dermatologists' guidelines for the management of onychomycosis 2014 , 2014, The British journal of dermatology.

[33]  J. Ocampo-Candiani,et al.  The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. , 2014, Journal of drugs in dermatology : JDD.

[34]  N. Zaias,et al.  Opportunistic toenail onychomycosis. The fungal colonization of an available nail unit space by non‐dermatophytes is produced by the trauma of the closed shoe by an asymmetric gait or other trauma. A plausible theory , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[35]  Aditya K Gupta,et al.  LUZU (luliconazole) 1% cream. , 2014, Skinmed.

[36]  Y. Ohno,et al.  Onychomycosis as a warning sign for peripheral arterial disease. , 2013, Acta dermato-venereologica.

[37]  B. Elewski,et al.  Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. , 2013, Journal of the American Academy of Dermatology.

[38]  J. Olin,et al.  Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. , 2013, Journal of drugs in dermatology : JDD.

[39]  K. Capriotti,et al.  Dimethyl sulfoxide: history, chemistry, and clinical utility in dermatology. , 2012, The Journal of clinical and aesthetic dermatology.

[40]  J. Appel,et al.  The asymmetric gait toenail unit sign. , 2012, SKINmed Dermatology for the Clinician.

[41]  R. Baran The nail in the elderly. , 2011, Clinics in dermatology.

[42]  B. Piraccini,et al.  Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. , 2010, Journal of the American Academy of Dermatology.

[43]  O. Pourquié,et al.  Rere controls retinoic acid signalling and somite bilateral symmetry , 2010, Nature.

[44]  M. A. Randhawa Dimethyl sulfoxide (DMSO) inhibits the germination of Candida albicans and the arthrospores of Trichophyton mentagrophytes. , 2008 .

[45]  Muhammad Akram Randhawa Dimethyl sulfoxide (DMSO) inhibits the germination of Candida albicans and the arthrospores of Trichophyton mentagrophytes. , 2008, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.

[46]  H. Maibach,et al.  In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. , 2007, Journal of pharmaceutical sciences.

[47]  B. Sigurgeirsson,et al.  Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. , 2002, Archives of dermatology.

[48]  B. Piraccini,et al.  Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.

[49]  J. Leyden,et al.  Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. , 1997, Journal of the American Academy of Dermatology.

[50]  A. Tosti,et al.  Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. , 1996, Journal of the American Academy of Dermatology.